- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04797091
Kidney in Coronavirus Disease 2019 Registry (KidneyCOVID19)
The SARS-CoV-2 virus is a virus newly identified in January 2020. The WHO defined COVID-19 as a health emergency of international importance. The clinical manifestation of the COVID-19 disease cannot be fully described in the short time.
First insights in patients suffering from acute kidney injury (AKI) during COVID-19 indicate severe course with high mortality. The locally varying spread of SARS CoV-2 infection requires a better understanding of clinical course of COVID-19 in order to be able to establish future treatment approaches.
The examination of attributable mortality and costs of COVID-19 will need to be studied on a multinational basis and therefore Kidney in COVID-19 Registry will particularly use a matched case control design.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The SARS-CoV-2 virus is a virus newly identified in January 2020 in Wuhan, China, which belongs to the group of coronaviruses and causes COVID-19. Due to the rapid spread worldwide, high morbidity and virulence the of causing SARS-CoV-2 , the WHO defined COVID-19 as a health emergency of international importance in February 2020. Due to the rapid spread of the new virus, a comprehensive understanding of the transmission, the course of the disease, the diagnosis and the therapeutic regimen is of the utmost importance. Initial case reports indicate that human-to-human transmission takes place through droplet infection. In contrast to previously known infections from the group of coronaviruses, the SARS-CoV-2 virus has a high ability to infect with already mild symptoms resulting in frequent outbreak situation of worldwide importance. Furthermore, high viral loads are found in the upper respiratory tract of infected people leading to the high virulence of causing SARS-CoV-2. The clinical manifestation of the COVID-19 disease cannot be fully described in the short time. However, symptoms of SARS-CoV-2 virus infection are described with mild symptoms like fever, muscle pain, and dry cough as well as severe complications like virus pneumonia, Acute Respiratory Distress Syndrome (ARDS) and death. Interestingly older and chronically ill patients in particular have a severe course of COVID-19 with intensive care treatment and high mortality. At present, there is no specific therapy available for COVID-19. Treatment approaches are primarily supportive with admission of patients to the intensive care unit (ICU), mechanical ventilation, extracorporeal membrane oxygenation (ECMO) and maintenance of fluid and electrolyte balance. Patients with severe renal insufficiency and fluid retention, pulmonary edema or hyperkalemia may require dialysis. First insights in patients suffering from acute kidney injury (AKI) during COVID-19 indicate severe course with high mortality. First case reports do not describe a beneficial effect of antiviral therapy. The locally varying spread of SARS CoV-2 infection requires a better understanding of clinical course of COVID-19 in order to be able to establish future treatment approaches. Investigators have to attach great importance to high-risk cohorts like patients suffering from chronic renal disease with many comorbidities or patients after kidney transplantation under immunosuppressive drug treatment. Although COVID-19 has been studied for only a few month it is known that especially these patients develop a severe clinical course. Due to increasingly frequent outbreak situations and globally chances in species distributions, local, as well as worldwide surveillances in epidemiology and species distribution are urgently needed. As the clinical course of COVID-19 disease is dependent on the causing viral pathogen and the full picture of clinical manifestation is not yet understand further studies with regard to the disease course are mandatory.
Additionally, the examination of attributable mortality and costs of COVID-19 will need to be studied on a multinational basis and therefore Kidney in COVID-19 Registry will particularly use a matched case control design.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Felix Köhler, MD
- Telefonnummer: +4922147897222
- E-Mail: felix.koehler@uk-koeln.de
Studieren Sie die Kontaktsicherung
- Name: Victor Suarez, MD
- Telefonnummer: +4922147897222
- E-Mail: victor.suarez@uk-koeln.de
Studienorte
-
-
-
Cologne, Deutschland, 50937
- Rekrutierung
- University Hospital of Cologne
-
Kontakt:
- Volker Burst, MD
- Telefonnummer: +49(0)221 478 86285
- E-Mail: volker.burst@uk-koeln.de
-
Kontakt:
- Victor Suarez, MD
- E-Mail: victor.suarez@uk-koeln.de
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Virology evidence of SARS-CoV-2-infection
- Pathological evidence of SARS-CoV-2-infection
Exclusion Criteria:
- Occurrence of ARDS (acute respiratory distress syndrome) without evidence of SARS-CoV-2 infection
- Acute kidney injury without evidence of SARS-CoV-2 infection
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Fallkontrolle
- Zeitperspektiven: Retrospektive
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Patients with SARS-CoV-2-infection
Patients with evidence of SARS-CoV-2-infection
|
Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
|
Control group
Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.
|
Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Determination of the global incidence of SARS-CoV-2 infections
Zeitfenster: 6 months
|
Determination of the global incidence of SARS-CoV-2 infections and the resulting effects on kidney function as well as monitoring of global and local developments over time.
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections
Zeitfenster: 6 months
|
Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections
|
6 months
|
Identification of risk groups and risk factors
Zeitfenster: 6 months
|
Identification of risk groups and risk factors by examining SARS-CoV-2 infections in patients with chronic kidney disease and kidney transplantation
|
6 months
|
Documentation of mortality rates due to SARS-CoV-2 infections
Zeitfenster: 6 months
|
Documentation of mortality rates in % in comparison to case controls enrolled in the same hospital
|
6 months
|
Documentation of additional costs due to SARS-CoV-2 infections
Zeitfenster: 6 months
|
Documentation of additional costs in euros in comparison to case controls enrolled in the same hospital
|
6 months
|
To assess increasing costs associated with SARS-CoV-2-infections
Zeitfenster: 6 months
|
To assess increasing costs associated with SARS-CoV-2-infections
|
6 months
|
To analyze the effect of SARS-CoV-2-infections on the kidney by means of eGFR
Zeitfenster: 6 months
|
To analyze the effect of SARS-CoV-2 infections on kidney function as determined by estimated Glomerular Filtration Rate (eGFR) after SARS-CoV-2 infection
|
6 months
|
To analyze the effect of SARS-CoV-2-infections on the kidney by means of maximum creatinine
Zeitfenster: 6 months
|
To analyze the effect of SARS-CoV-2 infections on kidney function as determined by maximum creatinine after SARS-CoV-2 infection
|
6 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Volker Burst, PD MD, University Hospital of Cologne
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Kidney in COVID-19
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur SARS-CoV-2
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNoch keine Rekrutierung
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Noch keine Rekrutierung
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeAktiv, nicht rekrutierend
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionAbgeschlossen
-
Indiana UniversityAbgeschlossenSARS-CoV-2Vereinigte Staaten
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District Hospital und andere MitarbeiterAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossen
-
University Hospital, Montpelliersociete SkillCell - 97198 Jarry; CNRS Alcediag UMR9005 - societe Sys2Diag -...Abgeschlossen
-
Argorna Pharmaceuticals Co., LTDAbgeschlossen
-
Argorna Pharmaceuticals Co., LTDAbgeschlossen
Klinische Studien zur Retrospective data collection
-
Acorai ABRekrutierung
-
Memorial Sloan Kettering Cancer CenterAbgeschlossenProstatakrebsVereinigte Staaten
-
Xim LimitedAbgeschlossenHerz-Kreislauf-Erkrankungen | Diabetes | Intensivpflege | Grundversorgung | Atemwegserkrankung | Trauma- und NotfallversorgungVereinigtes Königreich
-
Xim LimitedPortsmouth Hospitals NHS Trust; Mind Over Matter Medtech LtdAbgeschlossen
-
University of WarwickUniversity of BirminghamAbgeschlossen
-
Steno Diabetes Center CopenhagenUniversity of Southern Denmark; Steno Diabetes Center SjaellandAktiv, nicht rekrutierendWohlbefinden | Alkoholkonsum | Drogenkonsum | Essgewohnheiten | Rauchverhalten | Physische InaktivitätDänemark
-
GlaxoSmithKlineQuintiles IMSAbgeschlossen
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRekrutierungMukoviszidose | BiomarkerBelgien
-
Heinrich-Heine University, DuesseldorfChugai Pharma USA; Terumo BCTAbgeschlossenGesunde allogene Spender | Mobilisierter Granulozyten-Kolonie-stimulierender Faktor (G-CSF).Deutschland
-
IRCCS National Neurological Institute "C. Mondino...IRCCS Associazione Oasi Maria SS. ONLUS, Troina, Italy; IRCCS Istituto Auxologico... und andere MitarbeiterAbgeschlossenAlzheimer Erkrankung | Leichte kognitive EinschränkungItalien